Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment : results of a randomized phase II study
INTRODUCTION: The optimal treatment for patients with stage IIIA to IIIB non-small cell lung cancer (NSCLC) not eligible for surgery and definitive chemoradiotherapy is unknown. The aim of this study was to evaluate concurrent chemotherapy and palliative radiotherapy.
METHODS: Patients with stage IIIA to IIIB NSCLC with tumor >8 cm and/or forced expiratory volume < or =40%, performance status 0 to 2, and tumor-related chest symptoms were randomly assigned to arm A: radiotherapy alone (30 Gy/10 fractions) or arm B: chemoradiotherapy (two cycles of cisplatin and vinorelbine followed by radiotherapy together with third cycle). Primary end point was response rate, the power of the study was 90%, and the significance level was p = 0.1.
RESULTS: A total of 99 patients were eligible for response, overall survival, and progression-free survival evaluation. Median age was 66 years (45-78 years). Response rate was 27% versus 53%, p = 0.08; median overall survival was 9.0 versus 12.9 months, p = 0.0342; and median progression-free survival was 4.7 versus 7.3 months, p = 0.046, in arm A versus arm B, respectively. There were no deaths during treatment in arm A and six deaths in arm B; no hematological G3 to G4 toxicities in arm A and 14 toxicities in arm B. Symptom control was high and similar in both arms.
CONCLUSIONS: Upfront chemotherapy combined with palliative radiotherapy (30 Gy) is a promising treatment option in the subpopulation of patients with stage IIIA to IIIB NSCLC not amenable for definitive chemoradiotherapy and deserves further investigation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 5(2010), 8 vom: 01. Aug., Seite 1255-62 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nawrocki, Sergiusz [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5V9KLZ54CY |
|---|
| Anmerkungen: |
Date Completed 22.11.2010 Date Revised 01.12.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/JTO.0b013e3181e15d33 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM199241473 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM199241473 | ||
| 003 | DE-627 | ||
| 005 | 20231223214237.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/JTO.0b013e3181e15d33 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0664.xml |
| 035 | |a (DE-627)NLM199241473 | ||
| 035 | |a (NLM)20592630 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nawrocki, Sergiusz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment |b results of a randomized phase II study |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.11.2010 | ||
| 500 | |a Date Revised 01.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: The optimal treatment for patients with stage IIIA to IIIB non-small cell lung cancer (NSCLC) not eligible for surgery and definitive chemoradiotherapy is unknown. The aim of this study was to evaluate concurrent chemotherapy and palliative radiotherapy | ||
| 520 | |a METHODS: Patients with stage IIIA to IIIB NSCLC with tumor >8 cm and/or forced expiratory volume < or =40%, performance status 0 to 2, and tumor-related chest symptoms were randomly assigned to arm A: radiotherapy alone (30 Gy/10 fractions) or arm B: chemoradiotherapy (two cycles of cisplatin and vinorelbine followed by radiotherapy together with third cycle). Primary end point was response rate, the power of the study was 90%, and the significance level was p = 0.1 | ||
| 520 | |a RESULTS: A total of 99 patients were eligible for response, overall survival, and progression-free survival evaluation. Median age was 66 years (45-78 years). Response rate was 27% versus 53%, p = 0.08; median overall survival was 9.0 versus 12.9 months, p = 0.0342; and median progression-free survival was 4.7 versus 7.3 months, p = 0.046, in arm A versus arm B, respectively. There were no deaths during treatment in arm A and six deaths in arm B; no hematological G3 to G4 toxicities in arm A and 14 toxicities in arm B. Symptom control was high and similar in both arms | ||
| 520 | |a CONCLUSIONS: Upfront chemotherapy combined with palliative radiotherapy (30 Gy) is a promising treatment option in the subpopulation of patients with stage IIIA to IIIB NSCLC not amenable for definitive chemoradiotherapy and deserves further investigation | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Vinblastine |2 NLM | |
| 650 | 7 | |a 5V9KLZ54CY |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 650 | 7 | |a Vinorelbine |2 NLM | |
| 650 | 7 | |a Q6C979R91Y |2 NLM | |
| 700 | 1 | |a Krzakowski, Maciej |e verfasserin |4 aut | |
| 700 | 1 | |a Wasilewska-Tesluk, Ewa |e verfasserin |4 aut | |
| 700 | 1 | |a Kowalski, Dariusz |e verfasserin |4 aut | |
| 700 | 1 | |a Rucinska, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Dziadziuszko, Rafal |e verfasserin |4 aut | |
| 700 | 1 | |a Sowa, Aleksander |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer |d 2006 |g 5(2010), 8 vom: 01. Aug., Seite 1255-62 |w (DE-627)NLM169435504 |x 1556-1380 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2010 |g number:8 |g day:01 |g month:08 |g pages:1255-62 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/JTO.0b013e3181e15d33 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2010 |e 8 |b 01 |c 08 |h 1255-62 | ||